Latest Earnings Results: Q2 '26
Estimated EPS
-$0.06
Reported EPS
-$0.25
Surprise
-331.94%
Estimated Rev
$206.03M
Reported Rev
$190.7M
Surprise
-7.44%
$MYGN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.46 up 87.11% YoY • Reported revenue of $190.7M down -10.51% YoY • Myriad Genetics provides full-year 2026 financial guidance of $770 million to $790 million in revenue and expects an adjusted gross margin percentage in the range of 66% to 67%.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.14 | -- | -- | N/A |
Q2 '26 | -$0.06 | -$0.25 | -331.94% | MISSED |
Q1 '26 | -$0.07 | -$0.09 | -32.30% | MISSED |
Q4 '25 | -$0.01 | $0.04 | 367.97% | BEAT |
Q3 '25 | -$0.01 | $0.00 | 100.00% | BEAT |